Skye Bioscience Inc
NASDAQ:SKYE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
2.25
18
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Skye Bioscience Inc
Wall Street
Price Targets
SKYE Price Targets Summary
Skye Bioscience Inc
According to Wall Street analysts, the average 1-year price target for
SKYE
is 18.36 USD
with a low forecast of 14.14 USD and a high forecast of 22.05 USD.
SKYE Last Price Targets
Skye Bioscience Inc
The latest public price target was made on Sep 10, 2024 by
Jonathan Wolleben
from
JMP Securities
,
who expects
SKYE
stock to
rise by 456%
over the next 12 months.
You can read more about this price target by viewing
the article on TheFly.
| Analyst | Price Target | Date | Article |
|---|---|---|---|
Jonathan Wolleben
JMP Securities
|
15
USD
Upside 456% |
3 months ago
Sep 10, 2024
|
Skye Bioscience initiated with an Outperform at JMP Securities
TheFly
|
|
Albert Lowe
Craig-Hallum
|
18
USD
Upside 567% |
3 months ago
Aug 26, 2024
|
Craig-Hallum Reiterates Buy Rating on Skye Bioscience (SKYE)
StreetInsider
|
Jay Olson
Oppenheimer
|
21
USD
Upside 678% |
6 months ago
Jun 10, 2024
|
Skye Bioscience (SKYE) PT Lowered to $21 at Oppenheimer
StreetInsider
|
|
Kristen Kluska
Cantor Fitzgerald
|
21
USD
Upside 678% |
6 months ago
May 23, 2024
|
Skye Bioscience initiated with an Overweight at Cantor Fitzgerald
TheFly
|
|
Jay Olson
Oppenheimer
|
25
USD
Upside 826% |
8 months ago
Apr 11, 2024
|
Oppenheimer Starts Skye Bioscience (SYKE) at Outperform Following Uplisting to Nasdaq (correction)
StreetInsider
|
Edward Tenthoff
Piper Sandler
|
20
USD
Upside 641% |
9 months ago
Mar 14, 2024
|
Skye Bioscience (SKYE) PT Raised to $20 at Piper Sandler
StreetInsider
|
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is SKYE's stock price target?
Price Target
18.36
USD
According to Wall Street analysts, the average 1-year price target for
SKYE
is 18.36 USD
with a low forecast of 14.14 USD and a high forecast of 22.05 USD.
You don't have any saved screeners yet
